PRX-08066 Maleic acid

SKU: orb1685532

Description

PRX-08066 maleate is the salt form of PRX-08066, a potent and selective 5-HT2B receptor antagonist (IC50 = 3.4 nM). It is a research tool for investigating pulmonary arterial hypertension, demonstrating selective pulmonary vasodilation in both in vitro assays and in vivo animal models.

Research Area

Neuroscience, Pharmacology & Drug Discovery

Key Properties

• CAS Number: 866206-55-5
• MW: 517.96
• Purity: 97.59%
• Formula: C₂₃H₂₁ClFN₅O₄S
• SMILES: C(=C\C(O)=O)\C(O)=O.N(C1=C2C(SC(Cl)=C2)=NC=N1)C3CCN(CC4=CC(C#N)=C(F)C=C4)CC3
• Target: 5-HT Receptor
• Solubility: DMSO:96 mg/mL (185.34 mM);H2O:95 mg/mL (183.41 mM);Ethanol:91 mg/mL (175.69 mM)

Bioactivity

• Target IC50:
  5-HT2B:3.4 nM
• In Vivo:
  In a monocrotaline (MCT)-induced pulmonary arterial hypertension (PAH) rat model, PRX-08066 Maleic acid was orally administered at 50 or 100 mg/kg twice daily for 5 weeks. Hemodynamic measurements, MRI, and histological analyses were used to assess treatment effects. PRX-08066 Maleic acid significantly reduced pulmonary arterial pressure, improved right ventricular function, and attenuated right ventricular hypertrophy and pulmonary artery remodeling.
• In Vitro:
  PRX-08066 inhibits 5-HT-induced mitogen-activated protein kinase activation with IC50 of 12 nM and markedly reduces thymidine incorporation with IC50 of 3 nM in Chinese hamster ovary cells expressing the human 5-HT2BR, which suggests that PRX-08066 can potentially inhibit the pathologic 5-HT-induced vascular muscularization associated with PAH. PRX-08066 inhibits cell proliferation with IC50 of 0.46 nM and with a maximum inhibition of 20% and 5-HT secretion with IC50 of 6.9 nM with a maximum inhibition of 30% in the 5-HT(2B) expressing SI-NET cell line, KRJ-I. PRX-08066 inhibits isoproterenol-stimulated 5-HT release with IC50 of 1.25 nM and a maximum inhibition of 60% in NCI-H720 cells. PRX-08066 (0.5 nM) significantly inhibits ERK phosphorylation in KRJ-I cells. PRX-08066 inhibits TGFβ1, CTGF and FGF2 transcription and secretion in KRJ-I cells. PRX-08066 decreases level of transcripts for Ki67 (84%) as well as Ki67 protein (36.8%) associated with an increase in caspase 3 transcript levels in KRJ-I cells. PRX-08066 decreases level of transcripts of TGFβ1, FGF2 and TPH1 in KRJ-I cells. PRX-08066 significantly increases the number of dead cells (34%) compared with untreated controls in KRJ-I cells. PRX-08066 causes a significant increase in dead/caspase 3 positive cells (76%) and caspase 3 activity (52%) in HEK293 cells.
• Cell Research:
  5×103 cells/mL, seeds in 96-well plates at 100 μL (4 plates/experimental condition) are stimulated with PRX-08066 (0.1 μM to 100 nM: n = 6 wells/concentration). After 24 hours, mitochondrial activity is measured after adding MTT (3-[4,5-dimethylthiazol-2-ly]-2.5-diphenyltetrazolium bromide: 0.5 mg/mL per well) for 3 hours. The optical density is read photospectrometrically at 595 nm using a microplate reader. 29 Results are normalized to control (unstimulated cells) and the effective half-maximal concentrations calculated.(Only for Reference)

Storage & Handling

• Storage: store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

PRX-08066 maleate, PRX08066 Maleic acid, PRX-08066 Maleic acid, PRX 08066 Maleic acid, 5HTReceptor, 5HT Receptor, 5-HT2B

Compound Identifiers

PubChem CID

51348293